Screener / SEC EDGAR /CIK 0001739104 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Elanco Animal Health Inc ELAN

Compare with peers Embed
Earnings releases

Latest results release: Nov 6, 2026

8-K item 2.02, exhibit 99

What ELAN's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 6, 2026, ELAN reported $0.04 per share under GAAP and $0.27 on its own adjusted basis: the adjusted number is +575% above GAAP.

GAAP EPS $-0.29, release Feb 26, 2024: Net Loss of $141 million, Adjusted Net Income of $39 million ◦ Adjusted EBITDA of $165 million or 15.9% of Revenue ◦ Reported EPS of $(0.29), Adjusted EPS of $0.08 ◦ Net leverage r Adjusted EPS $0.08, release Feb 26, 2024: Adjusted Net Income of $39 million ◦ Adjusted EBITDA of $165 million or 15.9% of Revenue ◦ Reported EPS of $(0.29), Adjusted EPS of $0.08 ◦ Net leverage ratio of 5.6x Adjusted E 2024-02 GAAP EPS $0.06, release May 8, 2024: income of $32 million, Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34 ◦ Net leverage r Adjusted EPS $0.34, release May 8, 2024: Adjusted Net income of $167 million ◦ Adjusted EBITDA of $294 million, or 24.4% of Revenue ◦ Reported EPS of $0.06, Adjusted EPS of $0.34 ◦ Net leverage ratio of 6.1x Adjusted E +467% 2024-05 GAAP EPS $-0.10, release Aug 8, 2024: Net Loss of $50 million, Adjusted Net Income of $147 million ◦ Adjusted EBITDA of $275 million, or 23.2% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.30 ◦ Net leverage r Adjusted EPS $0.30, release Aug 8, 2024: Adjusted Net Income of $147 million ◦ Adjusted EBITDA of $275 million, or 23.2% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.30 ◦ Net leverage ratio of 5.6x Adjusted E 2024-08 GAAP EPS $0.73, release Nov 7, 2024: Income of $364 million, Adjusted Net Income of $66 million ◦ Adjusted EBITDA of $163 million, or 15.8% of Revenue ◦ Reported EPS of $0.73, Adjusted EPS of $0.13 ◦ Net leverage r Adjusted EPS $0.13, release Nov 7, 2024: Adjusted Net Income of $66 million ◦ Adjusted EBITDA of $163 million, or 15.8% of Revenue ◦ Reported EPS of $0.73, Adjusted EPS of $0.13 ◦ Net leverage ratio of 4.3x Adjusted E -82% 2024-11 GAAP EPS $-0.02, release Feb 25, 2025: late October rates ◦ Reported EPS of $(0.02), Adjusted EPS of $0.14 including an approximate $0.01 FX headwind vs. Adjusted EPS $0.14, release Feb 25, 2025: late October rates ◦ Reported EPS of $(0.02), Adjusted EPS of $0.14 including an approximate $0.01 FX headwind vs. 2025-02 GAAP EPS $0.13, release May 7, 2025: 4% organic constant currency growth ◦ Reported Net Income of $67 million, Adjusted Net Income of $184 million ◦ Adjusted EBITDA of $276 million, or 23.1% of Revenue ◦ Reported EPS of $0.13, Adjusted EPS of $0.37 ◦ Net leverage ratio of 4.4x Adjusted EBITDA Adjusted EPS $0.37, release May 7, 2025: 4% organic constant currency growth ◦ Reported Net Income of $67 million, Adjusted Net Income of $184 million ◦ Adjusted EBITDA of $276 million, or 23.1% of Revenue ◦ Reported EPS of $0.13, Adjusted EPS of $0.37 ◦ Net leverage ratio of 4.4x Adjusted EBITDA +185% 2025-05 GAAP EPS $0.02, release Aug 7, 2025: Adjusted EBITDA Margin of 19.2% ◦ Reported EPS of $0.02, Adjusted EPS of $0.26 ◦ Net leverage ratio of 4.0x Adj usted EBITDA Adjusted EPS $0.26, release Aug 7, 2025: Adjusted EBITDA Margin of 19.2% ◦ Reported EPS of $0.02, Adjusted EPS of $0.26 ◦ Net leverage ratio of 4.0x Adj usted EBITDA +1200% 2025-08 GAAP EPS $-0.07, release Nov 5, 2025: Adjusted EBITDA Margin of 17.5% ◦ Reported EPS of $(0.07), Adjusted EPS of $0.19 ◦ Net leverage ratio of 3.7 x Adj usted EBITDA Adjusted EPS $0.19, release Nov 5, 2025: Adjusted EBITDA Margin of 17.5% ◦ Reported EPS of $(0.07), Adjusted EPS of $0.19 ◦ Net leverage ratio of 3.7 x Adj usted EBITDA 2025-11 GAAP EPS $-0.56, release Feb 24, 2026: Adjusted EBITDA Margin of 16.7% ◦ Reported EPS of $(0.56), Adjusted EPS of $0.13 Adjusted EPS $0.13, release Feb 24, 2026: Adjusted EBITDA Margin of 16.7% ◦ Reported EPS of $(0.56), Adjusted EPS of $0.13 2026-02 GAAP EPS $0.11, release May 6, 2026: Adjusted EBITDA Margin of 24.5% ◦ Reported EPS of $0.11, Adjusted EPS of $0.40 ◦ Net leverage ratio of 3.5x Adjusted EBITDA Adjusted EPS $0.40, release May 6, 2026: Adjusted EBITDA Margin of 24.5% ◦ Reported EPS of $0.11, Adjusted EPS of $0.40 ◦ Net leverage ratio of 3.5x Adjusted EBITDA +264% 2026-05 GAAP EPS $0.11, release Aug 5, 2026: Adjusted EBITDA Margin of 21.2% ◦ Reported EPS of $0.11, Adjusted EPS of $0.34 ◦ Net leverage ratio of 3.1x A djusted EBITDA Adjusted EPS $0.34, release Aug 5, 2026: Adjusted EBITDA Margin of 21.2% ◦ Reported EPS of $0.11, Adjusted EPS of $0.34 ◦ Net leverage ratio of 3.1x A djusted EBITDA +209% 2026-08 GAAP EPS $0.04, release Nov 6, 2026: Adjusted EBITDA Margin of 19.5% ◦ Reported EPS of $0.04, Adjusted EPS of $0.27 ◦ Net leverage ratio of 2.9x Adjusted EBITDA Adjusted EPS $0.27, release Nov 6, 2026: Adjusted EBITDA Margin of 19.5% ◦ Reported EPS of $0.04, Adjusted EPS of $0.27 ◦ Net leverage ratio of 2.9x Adjusted EBITDA +575% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Adjusted EBITDA Margin of 19.5% ◦ Reported EPS of $0.04, Adjusted EPS of $0.27 ◦ Net leverage ratio of 2.9x Adjusted EBITDA release

What the company says its adjusted numbers leave out:

We use non-GAAP financial measures, such as revenue growth excluding the impact of acquisitions and divestitures, foreign exchange rate effects, royalty revenue and sales-based milestones sold to third party, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted gross profit, adjusted gross margin, net debt and net debt leverage to assess and analyze our operational results and trends as explained in more detail in the reconciliation tables later in this release. release Nov 6, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 6, 2026 · EX-99.1

Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

Open on SEC

Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected]

Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net Leverage Ratio Milestone

Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic constant currency growth

Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8% organic constant currency growth

Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year- over-year increase of 17% at midpoint

Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of 26% at midpoint

Improving year-end net leverage ratio target to approximately 2.9x Adjusted EBITDA with accelerated capital allocation flexibility

Building on expectations for full year 2026 outperformance, with continued expectation for 2027 results in line with December 2025 Investor Day annual algorithm: mid-single digit organic constant currency revenue growth, high- single digit Adjusted EBITDA growth, and low-double digit Adjusted EPS growth

- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2026, provided guidance for the fourth quarter of 2026, updated guidance for the full year 2026, and provided an early outlook for the full year 2027.

"Third quarter results demonstrate Elanco is a consistent, reliable growth company, delivering our diverse portfolio of innovation along with accelerating cash flow," stated Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 9% was led by International Pet Health up 17% and U.S. Pet Health up 13%, as we saw strong veterinarian and pet owner demand for what we believe is 'best medicine' innovation for our 'Big 6' growth led by Zenrelia and Credelio Quattro. Price accelerated to 4% growth, exceeding our expectations, while volume remained robust at 5%. Our durable top-line is fueled by a significant runway for share gains off a small base in large, growing, global markets. Both Zenrelia and Credelio Quattro reached new market share highs in September, with competitive activity having no fundamental impact on the trajectory of our innovation. At the same time, adjusted gross margin expanded 300 basis points, we invested in our commercial execution, and we drove our net leverage ratio to the 2.9x milestone which accelerates our capital allocation flexibility. As we are raising fu ll-year guidance to fully pass through the third quarter beat, Elanco is well positioned with momentum heading into 2027. We are recommitting to our annual algorithm of mid-single digit organic constant currency revenue growth, high- 1 single digit adjusted EBITDA growth, and low-double digit adjusted EPS growth, building on this year's expected outperformance and creating sustainable value for our customers, our shareholders, and the industry."

• Price increased 4% in Q3 led by global Pet Health at 5% including strong sequential acceleration in U.S. Pet Health versus Q2, as Elanco's differentiated innovation drives marketplace value

• Zenrelia™ achieved its largest revenue quarter ever, in both the U.S. and International, with September its largest month ever; U.S. JAK market share grew 7 points year-over-year with September its highest share month ever**; efficacy is driving use with 1,600 new clinics in Q3 to approximately 19,000 in the U.S.; gained 10 share points in Europe in H1 2026 (latest available data), 5x the competitive entrant, driven by high customer satisfaction***

• Credelio Quattro™ U.S. share grew 9 points year-over-year**; September was the largest sales month in Q3, and its highest share month ever**; continued clinic adoption momentum with 1,600 clinics added in Q3; total clinic penetration reaching over 16,500, or ~55%; Credelio Quattro became Elanco’s largest U.S. Pet Health branded product, surpassing Seresto U.S.

• Credelio Quattro received positive opinion from European Medicines Agency for expansion into the EU; expect to launch in Q1 2027, ahead of the season

• Befrena™ access now open across clinics, including corporates, with all outstanding orders expected to be filled by next week and move into full launch in Q1 2027. Portfolio effect is working as ~20% of clinics that bought Befrena had never used Zenrelia

• Global ruminants remained Elanco's fastest growing species, with revenue up 12% year-to-date on an organic constant currency basis or 17% including AHV International and foreign exchange rates, as innovation fortified the company's beef and dairy portfolio

• Elanco announced Jamie Preston as Executive Vice President and Chief People Officer effective November 3, succeeding Dave Kinard who intends to retire at the end of the year. Preston joins from Eli Lilly and Company, most recently serving as Vice President of HR, Global Compensation and Workforce Innovation

• Elanco achieved its highest employee engagement levels since IPO, with all functions growing engagement and outpacing enterprise benchmarks; momentum further validated by earning Great Place To Work® certifications in 11 markets where the company operates

(1) Organic CC Growth represents revenue growth excluding royalty revenue and sales-based milestones that were sold to a third party, the impact of foreign exchange rates, and revenue attributable to AHV International B.V., which was acquired on April 30, 2026.

(2) Primarily represents royalty revenue, sales-based milestones and revenue from arrangements in which we manufacture products on behalf of a third party. Royalty revenue and sales-based milestones sold to a third party, to which we are no longer entitled but are still required to be recognized as revenue under GAAP, totaled $21 million and $6 million for the three months ended September 30, 2026 and 2025, respectively. 2 In the third quarter of 2026, revenue was $1,265 million, an increase of 11% on a reported basis, or 9% on an organic constant currency basis, compared to the third quarter of 2025.

revenue was $608 million, an increase of 14% on both a reported and an organic constant currency basis. The 5% increase from price exceeded the company's expectation for acceleration. The year-over-year volume increase of 9% in the third quarter was primarily driven by strong demand for Zenrelia , Credelio Quattro and AdTab™ . The Advantage® Family of products and Seresto® Family of products contributed revenue of $115 million and $49 million, respectively; Seresto was negatively impacted by U.S. retailer inventory draw down, with underlying performance in line with expectations.

revenue was $631 million, an increase of 6% on a reported basis, or 4% on an organic constant currency basis. The year-over-year reported increase was primarily driven by a 3% increase in price during the period and a 2% contribution from AHV.

Gross profit was $720 million and gross margin percentage was 56.9% in the third quarter of 2026, an increase of 350 basis points compared to the third quarter of 2025. On an adjusted basis, gross profit was $699 million and gross margin percentage was 56.1% in the third quarter of 2026, an increase of 300 basis points compared to the third quarter of 2025. The increase in gross margin percentage on both a reported and adjusted basis, which was ahead of the company's expectations, was primarily driven by increased pricing and favorable mix from the strong performance in U.S. Pet Health and global ruminants.

Total operating expenses were $492 million for the third quarter of 2026, an increase of 12% compared to the third quarter of 2025. Marketing, selling and administrative expenses increased 12% to $393 million, driven by higher compensation expense and strategic investments in the global launches of new products. Research and development expenses increased 11% to $99 million.

Asset impairment, restructuring and other special charges were $3 million in the third quarter of 2026, compared to $25 million in the third quarter of 2025. Charges recorded in the third quarter of 2026 primarily related to the company's 2025 restructuring plan as well as costs associated with the acquisition of AHV.

Reported net interest expense was $59 million in the third quarter of 2026, an increase of $7 million compared to the third quarter of 2025. The increase was principally due to the maturity of interest rate swaps in September 2025, which generated a favorable impact to interest expense in the prior year period, as well as imputed interest on our liability for sale of future revenue. These increases were partially offset by lower average debt balances. Adjusted net interest expense, which excludes this imputed interest, was $41 million in the third quarter of 2026, an increase of $7 million compared to the third quarter of 2025.

The reported effective tax rate was 25.7% in the third quarter of 2026 compared to 30.9% in the third quarter of 2025 . This decrease was primarily due to a more favorable jurisdictional mix of earnings and the absence of prior-year discrete tax changes. The adjusted effective tax rate was 19.4% in the third quarter of 2026 compared to 26.5% in the third quarter of 2025.

Net income for the third quarter of 2026 was $18 million, or $0.04 per diluted share on a reported basis, compared with net loss of $34 million, or $0.07 per diluted share, for the same period in 2025. On an adjusted basis, net income for the third quarter 2026 grew 45% compared to the same period in 2025 to $136 million, representing $0.27 per diluted share.

Adjusted EBITDA was $243 million in the third quarter of 2026, a 23% increase compared to the third quarter of 2025. Adjusted EBITDA margin was 19.5% compared with 17.5% for the third quarter of 2025.

Cas h provided by operations was $216 million in the third quarter of 2026, compared to cash provided by operations of $219 million in the third quarter of 2025.

As of September 30, 2026, Elanco’s net leverage ratio was 2.9x adjusted EBITDA, a decrease of 0.7x compared to December 31, 2025. 3

Elanco is updating financial guidance for the full year 2026, summarized in the following table:

2026 Full Year (dollars in August November millions, except per Guidance Guidance share amounts) Revenue(1) $5,090 to $5,140 $5,155 to $5,180 Adjusted EBITDA $1,010 to $1,035 $1,050 to $1,065 Adjusted Earnings $1.10 to $1.16 $1.17 to $1.20 per Share

(1) Revenue guidance excludes royalty revenue and sales-based milestones that were sold to a third party.

"Elanco achieved significant adjusted gross margin expansion in the third quarter, up 300 basis points reflecting accelerating price gains to 4% year- over-year and beneficial mix, as well as early progress on our Elanco Ascend productivity initiatives," said Bob VanHimbergen, Executive Vice President and CFO of Elanco Animal Health. "At the same time, we have continued our high-ROI investments in our launches. Our consistent top-line growth and improved profitability, alongside working capital discipline, have increased free cash flow and brought our net leverage ratio to 2.9x at quarter-end. Reaching this key milestone earlier than anticipated now unlocks accelerated capital allocation flexibility."

The company anticipates a tailwind to revenue of approximately $60 million from the favorable impact of foreign exchange rates compared to prior year. Excluding the impacts of foreign exchange rates, the AHV International acquisition that closed in April 2026, and royalty revenue and sales-based milestones sold to a third party, the company now expects revenue growth of approximately 8% versus 6% to 7% previously. The company continues to expect an accelerating contribution from price versus 2025.

Elanco expects adjusted gross margin of 55.8% to 56.0%, an increase of 100 basis points versus 2025 and compared to the prior expectation of 50 basis points of improvement. Adjusted EBITDA guidance reflects savings from the Elanco Ascend initiative as well as incremental strategic investments in the global launches of the company's innovation portfolio and the advancement of the R&D pipeline.

Additionally, the company is providing guidance for the fourth quarter of 2026, as summarized in the following table:

2026 Fourth Quarter Guidance (dollars in millions, except per share amounts) Revenue(1) $1,190 to $1,215 Adjusted EBITDA $185 to $200 Adjusted Earnings per Share $0.16 to $0.19

(1) Revenue guidance excludes royalty revenue and sales-based milestones that were sold to a third party.

In the fourth quarter, the company anticipates a minimal impact from foreign exchange rates compared to prior year. Excluding the impacts of foreign exchange rates, the AHV International acquisition that closed in April 2026, and royalty revenue and sales-based milestones sold to a third party, the company expects 4% to 6% revenue growth. The company expects operating expenses up approximately 11% year-over-year in constant currency with incremental support for innovation products and R&D investments.

The 2026 full year and fourth quarter financial guidance reflects foreign exchange rates as of the end of October. Further details on guidance, including GAAP reported to non-GAAP adjusted reconciliations, are included in the financial tables of this press release and will be discussed on the company's conference call this morning. 4

Elanco will host a webcast and conference call at 8:00 a.m. Eastern Time today, during which company executives will review third quarter financial and operational results, discuss fourth quarter and full year 2026 financial guidance, provide an early outlook for the full year 2027, and respond to questions from analysts. Investors, analysts, members of the media and the public may access the live webcast and accompanying slides by visiting the Elanco website at https://investor.elanco.com and selecting Events and Presentations. A replay of the webcast will be archived and made available a few hours after the event on the company's website, at https://investor.elanco.com/news-events/events-presentation.

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With more than 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2026 full year and fourth quarter guidance and long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important risk factors that could cause actual results to differ materially from those in the forward- looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including but not limited to the following:

• the success of our research and development (R&D), regulatory approval and licensing efforts;

• the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;

• an increased use of alternative distribution channels or changes within existing distribution channels;

• our ability to complete acquisitions and divestitures and to successfully integrate the businesses we acquire;

• our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;

• manufacturing problems and capacity imbalances, including at our contract manufacturers;

• our dependence on sophisticated information technology systems and infrastructure, including the use of third-party, cloud-based technologies, and the impact of outages or breaches of the information technology systems and infrastructure we rely on;

• the impact of weather conditions, including those related to climate change, and the availability of natural resources; 5 • demand, supply and operational challenges associated with the effects of a human disease outbreak, epidemic, pandemic or other widespread public health concern;

• the effect of our substantial indebtedness on our business, including restrictions in our debt agreements that limit our operating flexibility and changes in our credit ratings that lead to higher borrowing expenses and restrict access to credit;

• risks related to the write-down of goodwill or identifiable intangible assets;

• the lack of availability or significant increases in the cost of raw materials;

• risks related to foreign and domestic economic, political, legal and business environments;

• our current plan not to pay dividends and restrictions on our ability to pay dividends;

• the potential impact that actions by activist shareholders could have on the pursuit of our business strategies;

• actions by regulatory bodies, including as a result of their interpretation of studies on product safety;

• the possible slowing or cessation of acceptance and/or adoption of our farm animal sustainability initiatives;

• the impact of increased regulation or decreased governmental financial support related to the raising, processing or consumption of farm animals;

• risks related to tariffs, trade protection measures or other modifications of foreign trade policy;

• the impact of litigation, regulatory investigations and other legal matters, including the risk to our reputation and the risk that our insurance policies may be insufficient to protect us from the impact of such matters;

• challenges to our intellectual property rights or our alleged violation of rights of others;

• unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;

• inability to achieve our aspirations or meet the expectations of stakeholders with respect to environmental, social and governance matters.

For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company’s latest Form 10-K and Form 10-Qs filed with the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this press release. If any of these risks materialize, or if any of the above assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should be viewed as historical data. 6

We use non-GAAP financial measures, such as revenue growth excluding the impact of acquisitions and divestitures, foreign exchange rate effects, royalty revenue and sales-based milestones sold to third party, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted gross profit, adjusted gross margin, net debt and net debt leverage to assess and analyze our operational results and trends as explained in more detail in the reconciliation tables later in this release.

We believe these non-GAAP financial measures are useful to investors because they provide greater transparency regarding our operating performance. Reconciliation of non-GAAP financial measures and reported U.S. generally accepted accounting principles (GAAP) financial measures are included in the tables accompanying this press release and are posted on our website at www.elanco.com. The primary material limitations associated with the use of such non-GAAP measures as compared to GAAP results include the following: (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they exclude financial information and events, such as the effects of an acquisition or divestiture or amortization of intangible assets, that some may consider important in evaluating our performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not exclude all unusual or non-recurring items, which could increase or decrease these measures, which investors may consider to be unrelated to our long-term operations. These non-GAAP measures are not, and should not, be viewed as substitutes for GAAP reported measures. We encourage investors to review our unaudited consolidated financial statements in their entirety and caution investors to use GAAP measures as the primary means of evaluating our performance, value and prospects for the future, and non-GAAP measures as supplemental measures.

We use our website to disclose important company information to investors, customers, employees and others interested in Elanco. We encourage investors to consult our website regularly for important information about Elanco, including an Investor Overview presentation containing a general overview of the business, which can be found in the Events and Presentations page of our website.

We define innovation revenue as revenue from new products, lifecycle management and certain geographic expansions and business development transactions that is incremental in reference to product revenue in 2020 and does not include the expected impact of cannibalization on the base portfolio.

We define organic constant currency revenue growth as revenue growth excluding royalty revenue and sales-based milestones that were sold to a third party, the impact of foreign exchange rates, and revenue attributable to AHV International B.V., which was acquired on April 30, 2026. 7

(Dollars and shares in millions, except per share data) We use non-GAAP financial measures, such as organic constant currency revenue growth, adjusted gross profit, adjusted gross margin percentage, adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA and adjusted EBITDA margin and net debt and net debt leverage, that differ from financial measures reported in conformity with GAAP. The company believes these non-GAAP measures provide useful information to investors. Among other things, they may help investors assess and analyze our operational results and trends of our ongoing operations. Management also uses these non-GAAP measures internally to evaluate the performance of the business and in making resource allocation decisions. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. Reconciliation of non-GAAP financial measures and reported GAAP financial measures are included in the tables below.

We define gross profit as total revenue less cost of sales. We define adjusted gross profit as gross profit less royalty revenue and sales-based milestones sold to a third party, less cost of sales adjustments. We define adjusted gross margin percentage as adjusted gross profit divided by total revenue, less royalty revenue and sales-based milestones sold to a third party. The following is a reconciliation of GAAP reported gross profit for the three and nine months ended September 30, 2026 and 2025, to adjusted gross profit and adjusted gross margin percentage:

We define adjusted net income as net income excluding amortization of intangible assets, purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gains on sales of assets and related costs, facility exit costs, the impacts from sales of future revenues, gains and losses on mark-to-market adjustments on equity securities, tax valuation allowances, certain litigation-related settlements that we consider to be unusual or infrequent and significant, and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations adjusted for income tax expense associated with the excluded financial items. We define adjusted earnings per share as adjusted net income divided by the number of weighted-average diluted shares outstanding for the applicable period. The following is a reconciliation of GAAP reported net income and EPS for the three months ended September 30, 2026 and 2025, to adjusted net income and EPS:

9 (a) Adjustments to GAAP reported net income to arrive at adjusted net income for the three months ended September 30, 2026 and 2025, included the following:

(1) Adjustments of $25 million for the three months ended September 30, 2025, primarily related to two early-stage capital projects totaling $16 million that were indefinitely suspended during the third quarter.

(2) Adjustments of $18 million for the three months ended September 30, 2026, primarily related to imputed interest expense on our liability for sale of future revenue. Adjustments of $18 million for the three months ended September 30, 2025, primarily related to $13 million of imputed interest expense on our liability for sale of future revenue, and to a lesser degree, the write-off of previously deferred financing costs, given accelerated principal repayments.

(3) Adjustments of $26 million for the three months ended September 30, 2026, primarily represented the income tax expense associated with the adjusted items discussed above. Adjustments of $50 million for the three months ended September 30, 2025 primarily represented the income tax expense associated with the adjusted items discussed above and the discrete tax impact from the remeasurement of certain deferred tax positions due to a foreign tax rate change.

The following is a reconciliation of GAAP reported net income and EPS for the nine months ended September 30, 2026 and 2025, to adjusted net income and EPS:

(a) Adjustments to GAAP reported net income to arrive at adjusted net income for the nine months ended September 30, 2026 and 2025, included the following:

(1) Adjustments of $28 million for the nine months ended September 30, 2026, primarily related to $18 million of restructuring charges ($15 million of which was non-cash shut-down costs for the animal studies portion of our R&D facilities in Monheim, Germany) associated with our 2025 Restructuring Plan, as well as costs associated with our acquisition of AHV ($5 million). Adjustments of $35 million for the nine months ended September 30, 2025, included two early- stage capital projects totaling $16 million that were indefinitely suspended during the third quarter of 2025 and $7 million of upfront payments made in relation to new licensing arrangements.

(2) Adjustments of $47 million for the nine months ended September 30, 2026, primarily related to imputed interest expense on our liability for sale of future revenue. Adjustments of $28 million for the nine months ended September 30, 2025, primarily related to $20 million of imputed interest expense on our liability for sale of future revenue and the write-off of previously deferred financing costs, given accelerated principal repayments made throughout 2025.

(3) Adjustments of $15 million for the nine months ended September 30, 2026, primarily related to currency translation losses reclassified from accumulated other comprehensive loss in conjunction with the substantial liquidation of a dormant legal entity, a litigation settlement, and mark-to-market adjustments on equity investments.

(4) Adjustments of $87 million for the nine months ended September 30, 2026, primarily represented the income tax expense associated with the adjusted items discussed above. A djustments of $98 million for the nine months ended September 30, 2025, primarily represented the income tax expense associated with the adjusted items discussed above and the discrete tax impacts from the remeasurement of certain deferred tax positions due to foreign tax rate changes, partially offset by a $35 million benefit related to a discrete tax item recognized during the first quarter of 2025. 10

We define adjusted EBITDA as net income (loss) adjusted for interest expense (income), which includes debt financing charges and imputed interest on our liability for sale of future revenue, income tax expense (benefit) and depreciation and amortization, further adjusted to exclude purchase accounting adjustments to inventory, acquisition and divestiture-related charges, including integration and separation costs, severance, goodwill and other asset impairments, gains on sales of assets and related costs, facility exit costs, revenue sold to a third party, gains and losses on mark-to-market adjustments on equity securities, certain litigation-related settlements which we consider to be unusual or infrequent and significant, and other specified significant items, such as unusual or non-recurring items that are unrelated to our long-term operations.

For the periods presented, we have not made adjustments for all items that may be considered unrelated to our long-term operations. We believe adjusted EBITDA, when used in conjunction with our results presented in accordance with GAAP and its reconciliation to net income (loss), enhances investors' understanding of our performance, valuation and prospects for the future. We also believe adjusted EBITDA is a measure used in the animal health industry by analysts as a valuable performance metric for investors. The following is a reconciliation of GAAP reported net income (loss) for the three and nine months ended September 30, 2026 and 2025, to EBITDA, adjusted EBITDA and adjusted EBITDA margin, which we define as adjusted EBITDA divided by total revenue, less royalty revenue and sales-based milestones sold to a third party, fo r the respective periods:

We define gross debt as the sum of the current portion of long-term debt and long-term debt excluding unamortized debt issuance costs. We define net debt as gross debt less cash and cash equivalents and finance lease liabilities on the balance sheet. We define our net leverage ratio as net debt divided by our trailing twelve month adjusted EBITDA. We believe our net debt and net leverage ratio are important measures to monitor our financial flexibility, liquidity and capital structure and may enhance investors' understanding of our ability to meet future financial obligations. In addition, a net leverage ratio is a financial measure that is frequently used by investors and creditors. The below calculations do not include covenant-related adjustments that reduce our net leverage ratio. The following is a reconciliation of gross debt to net debt as of September 30, 2026:

Long-term debt $ 3,633 Current portion of long-term debt 74 Less: Unamortized debt issuance costs -21 Total gross debt 3,728 Less: Cash and cash equivalents 465 Less: Finance lease liabilities 258 Net debt $ 3,005

The following table presents a calculation of our net leverage ratio as of September 30, 2026:

Net debt $ 3,005 Trailing twelve month adjusted EBITDA 1,053 Net leverage ratio 2.9x

Full text with the tables
                                                                    Exhibit 99.1
                                                                                
   FOR IMMEDIATE RELEASE                                                        
                                                                                
Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected]

Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected]
                                                                                
            Elanco Animal Health Reports Third Quarter 2026 Results             
                                                                                
 Accelerated Price, Organic Constant Currency Revenue Growth, and Gross Margin  
 Expansion; Raising Full Year Outlook and Innovation Target; Achieved 2.9x Net  
                            Leverage Ratio Milestone                            
                                                                                
  •                                                                             
                                                                                
Third Quarter 2026 Financial Results:
                                                                                
  ◦                                                                             
                                                                                
Revenue of $1.265 billion, an increase of 11% year-over-year; 9% organic
constant currency growth
                                                                                
  ◦                                                                             
                                                                                
Reported Net Income of $18 million, Adjusted Net Income of $136 million
                                                                                
  ◦                                                                             
                                                                                
Adjusted EBITDA of $243 million; Adjusted EBITDA Margin of 19.5%
                                                                                
  ◦                                                                             
                                                                                
                                                                                
  Reported EPS of $0.04, Adjusted EPS of $0.27                                  
                                                                                
                                                                                
  ◦                                                                             
                                                                                
                                                                                
  Net leverage ratio of 2.9x Adjusted EBITDA                                    
                                                                                
• Full Year 2026 Guidance:
                                                                                
  ◦                                                                             
                                                                                
Raising innovation revenue target to $1.275 billion
                                                                                
  ◦                                                                             
                                                                                
Raising revenue guidance to $5.155 billion to $5.18 billion, or approximately 8%
organic constant currency growth
                                                                                
  ◦                                                                             
                                                                                
Raising Adjusted EBITDA guidance to $1.05 billion to $1.065 billion, a year-
over-year increase of 17% at midpoint
                                                                                
  ◦                                                                             
                                                                                
Raising Adjusted EPS guidance to $1.17 to $1.20, a year-over-year increase of
26% at midpoint
                                                                                
  ◦                                                                             
                                                                                
Improving year-end net leverage ratio target to approximately 2.9x Adjusted
EBITDA with accelerated capital allocation flexibility
                                                                                
  •                                                                             
                                                                                
2027 Early Outlook:
                                                                                
  ◦                                                                             
                                                                                
Building on expectations for full year 2026 outperformance, with continued
expectation for 2027 results in line with December 2025 Investor Day annual
algorithm: mid-single digit organic constant currency revenue growth, high-
single digit Adjusted EBITDA growth, and low-double digit Adjusted EPS growth
                                                                                
  Indianapolis, IN (                                                            
                                                                                
                                                                                
  November 6, 2026                                                              
                                                                                
                                                                                
  )                                                                             
                                                                                
- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial
results for the third quarter of 2026, provided guidance for the fourth quarter
of 2026, updated guidance for the full year 2026, and provided an early outlook
for the full year 2027.

"Third quarter results demonstrate Elanco is a consistent, reliable growth
company, delivering our diverse portfolio of innovation along with accelerating
cash flow," stated Jeff Simmons, President and CEO of Elanco. "Organic constant
currency revenue growth of 9% was led by International Pet Health up 17% and
U.S. Pet Health up 13%, as we saw strong veterinarian and pet owner demand for
what we believe is 'best medicine' innovation for our 'Big 6' growth led by
Zenrelia and Credelio Quattro. Price accelerated to 4% growth, exceeding our
expectations, while volume remained robust at 5%. Our durable top-line is fueled
by a significant runway for share gains off a small base in large, growing,
global markets. Both Zenrelia and Credelio Quattro reached new market share
highs in September, with competitive activity having no fundamental impact on
the trajectory of our innovation. At the same time, adjusted gross margin
expanded 300 basis points, we invested in our commercial execution, and we drove
our net leverage ratio to the 2.9x milestone which accelerates our capital
allocation flexibility. As we are raising fu ll-year guidance to fully pass
through the third quarter beat, Elanco is well positioned with momentum heading
into 2027. We are recommitting to our annual algorithm of mid-single digit
organic constant currency revenue growth, high-
                                       1                                        
single digit adjusted EBITDA growth, and low-double digit adjusted EPS growth,
building on this year's expected outperformance and creating sustainable value
for our customers, our shareholders, and the industry."
                                                                                
   Select Business Highlights Since the Last Earnings Call                      
                                                                                
• Price increased 4% in Q3 led by global Pet Health at 5% including strong
sequential acceleration in U.S. Pet Health versus Q2, as Elanco's differentiated
innovation drives marketplace value

• Zenrelia™ achieved its largest revenue quarter ever, in both the U.S. and
International, with September its largest month ever; U.S. JAK market share grew
7 points year-over-year with September its highest share month ever**; efficacy
is driving use with 1,600 new clinics in Q3 to approximately 19,000 in the U.S.;
gained 10 share points in Europe in H1 2026 (latest available data), 5x the
competitive entrant, driven by high customer satisfaction***

• Credelio Quattro™ U.S. share grew 9 points year-over-year**; September was the
largest sales month in Q3, and its highest share month ever**; continued clinic
adoption momentum with 1,600 clinics added in Q3; total clinic penetration
reaching over 16,500, or ~55%; Credelio Quattro became Elanco’s largest U.S. Pet
Health branded product, surpassing Seresto U.S.

• Credelio Quattro received positive opinion from European Medicines Agency for
expansion into the EU; expect to launch in Q1 2027, ahead of the season

• Befrena™ access now open across clinics, including corporates, with all
outstanding orders expected to be filled by next week and move into full launch
in Q1 2027. Portfolio effect is working as ~20% of clinics that bought Befrena
had never used Zenrelia

• Global ruminants remained Elanco's fastest growing species, with revenue up
12% year-to-date on an organic constant currency basis or 17% including AHV
International and foreign exchange rates, as innovation fortified the company's
beef and dairy portfolio

• Elanco announced Jamie Preston as Executive Vice President and Chief People
Officer effective November 3, succeeding Dave Kinard who intends to retire at
the end of the year. Preston joins from Eli Lilly and Company, most recently
serving as Vice President of HR, Global Compensation and Workforce Innovation

• Elanco achieved its highest employee engagement levels since IPO, with all
functions growing engagement and outpacing enterprise benchmarks; momentum
further validated by earning Great Place To Work® certifications in 11 markets
where the company operates

**Per Kynetec data

***Internal estimates based on multiple data sources
                                                                                
  Financial Results                                                             
                                                                                
                                                                                
  Third Quarter                                                                 
  Results                                                                       
  (dollars in                                            Organic CC             
  millions,          2026       2025         Change (%)  Growth(1)(%)           
  except per                                                                    
  share                                                                         
  amounts)                                                                      
  Pet Health         $608       $533     14  %                           14  %  
  Farm Animal        $631       $593      6  %                            4  %  
  Cattle             $339       $289     17  %                           11  %  
  Poultry            $201       $217     -7  %                           -7  %  
  Swine               $91        $87      5  %                            5  %  
  Contract                                                                      
  Manufacturing       $26        $11    136  %                                  
  and Other(2)                                                                  
  Total Revenue    $1,265     $1,137     11  %                            9  %  
  Gross Profit       $720       $607     19  %                                  
  Reported Net        $18      $(34)         NM                                 
  Income (Loss)                                                                 
  Adjusted           $243       $198     23  %                                  
  EBITDA                                                                        
  Reported EPS      $0.04    $(0.07)         NM                                 
  Adjusted EPS      $0.27      $0.19     42  %                                  
                                                                                
NM - Not meaningful

(1) Organic CC Growth represents revenue growth excluding royalty revenue and
sales-based milestones that were sold to a third party, the impact of foreign
exchange rates, and revenue attributable to AHV International B.V., which was
acquired on April 30, 2026.

(2) Primarily represents royalty revenue, sales-based milestones and revenue
from arrangements in which we manufacture products on behalf of a third party.
Royalty revenue and sales-based milestones sold to a third party, to which we
are no longer entitled but are still required to be recognized as revenue under
GAAP, totaled $21 million and $6 million for the three months ended September
30, 2026 and 2025, respectively.
                                       2                                        
In the third quarter of 2026, revenue was $1,265 million, an increase of 11% on
a reported basis, or 9% on an organic constant currency basis, compared to the
third quarter of 2025.
                                                                                
  Pet Health                                                                    
                                                                                
revenue was $608 million, an increase of 14% on both a reported and an organic
constant currency basis. The 5% increase from price exceeded the company's
expectation for acceleration. The year-over-year volume increase of 9% in the
third quarter was primarily driven by strong demand for Zenrelia , Credelio
Quattro and AdTab™ . The Advantage® Family of products and Seresto® Family of
products contributed revenue of $115 million and $49 million, respectively;
Seresto was negatively impacted by U.S. retailer inventory draw down, with
underlying performance in line with expectations.
                                                                                
  Farm Animal                                                                   
                                                                                
revenue was $631 million, an increase of 6% on a reported basis, or 4% on an
organic constant currency basis. The year-over-year reported increase was
primarily driven by a 3% increase in price during the period and a 2%
contribution from AHV.

Gross profit was $720 million and gross margin percentage was 56.9% in the third
quarter of 2026, an increase of 350 basis points compared to the third quarter
of 2025. On an adjusted basis, gross profit was $699 million and gross margin
percentage was 56.1% in the third quarter of 2026, an increase of 300 basis
points compared to the third quarter of 2025. The increase in gross margin
percentage on both a reported and adjusted basis, which was ahead of the
company's expectations, was primarily driven by increased pricing and favorable
mix from the strong performance in U.S. Pet Health and global ruminants.

Total operating expenses were $492 million for the third quarter of 2026, an
increase of 12% compared to the third quarter of 2025. Marketing, selling and
administrative expenses increased 12% to $393 million, driven by higher
compensation expense and strategic investments in the global launches of new
products. Research and development expenses increased 11% to $99 million.

Asset impairment, restructuring and other special charges were $3 million in the
third quarter of 2026, compared to $25 million in the third quarter of 2025.
Charges recorded in the third quarter of 2026 primarily related to the company's
2025 restructuring plan as well as costs associated with the acquisition of AHV.

Reported net interest expense was $59 million in the third quarter of 2026, an
increase of $7 million compared to the third quarter of 2025. The increase was
principally due to the maturity of interest rate swaps in September 2025, which
generated a favorable impact to interest expense in the prior year period, as
well as imputed interest on our liability for sale of future revenue. These
increases were partially offset by lower average debt balances. Adjusted net
interest expense, which excludes this imputed interest, was $41 million in the
third quarter of 2026, an increase of $7 million compared to the third quarter
of 2025.

The reported effective tax rate was 25.7% in the third quarter of 2026 compared
to 30.9% in the third quarter of 2025 . This decrease was primarily due to a
more favorable jurisdictional mix of earnings and the absence of prior-year
discrete tax changes. The adjusted effective tax rate was 19.4% in the third
quarter of 2026 compared to 26.5% in the third quarter of 2025.

Net income for the third quarter of 2026 was $18 million, or $0.04 per diluted
share on a reported basis, compared with net loss of $34 million, or $0.07 per
diluted share, for the same period in 2025. On an adjusted basis, net income for
the third quarter 2026 grew 45% compared to the same period in 2025 to $136
million, representing $0.27 per diluted share.

Adjusted EBITDA was $243 million in the third quarter of 2026, a 23% increase
compared to the third quarter of 2025. Adjusted EBITDA margin was 19.5% compared
with 17.5% for the third quarter of 2025.
                                                                                
  Working Capital and Balance Sheet                                             
                                                                                
Cas h provided by operations was $216 million in the third quarter of 2026,
compared to cash provided by operations of $219 million in the third quarter of
2025.

As of September 30, 2026, Elanco’s net leverage ratio was 2.9x adjusted EBITDA,
a decrease of 0.7x compared to December 31, 2025.
                                       3                                        
                                                                                
  Financial Guidance                                                            
                                                                                
Elanco is updating financial guidance for the full year 2026, summarized in the
following table:
                                                                                
  2026 Full Year                                                                
  (dollars in               August                    November                  
  millions, except per    Guidance                    Guidance                  
  share amounts)                                                                
  Revenue(1)                $5,090    to    $5,140      $5,155    to    $5,180  
  Adjusted EBITDA           $1,010    to    $1,035      $1,050    to    $1,065  
  Adjusted Earnings          $1.10    to     $1.16       $1.17    to     $1.20  
  per Share                                                                     
                                                                                
(1) Revenue guidance excludes royalty revenue and sales-based milestones that
were sold to a third party.

"Elanco achieved significant adjusted gross margin expansion in the third
quarter, up 300 basis points reflecting accelerating price gains to 4% year-
over-year and beneficial mix, as well as early progress on our Elanco Ascend
productivity initiatives," said Bob VanHimbergen, Executive Vice President and
CFO of Elanco Animal Health. "At the same time, we have continued our high-ROI
investments in our launches. Our consistent top-line growth and improved
profitability, alongside working capital discipline, have increased free cash
flow and brought our net leverage ratio to 2.9x at quarter-end. Reaching this
key milestone earlier than anticipated now unlocks accelerated capital
allocation flexibility."

The company anticipates a tailwind to revenue of approximately $60 million from
the favorable impact of foreign exchange rates compared to prior year. Excluding
the impacts of foreign exchange rates, the AHV International acquisition that
closed in April 2026, and royalty revenue and sales-based milestones sold to a
third party, the company now expects revenue growth of approximately 8% versus
6% to 7% previously. The company continues to expect an accelerating
contribution from price versus 2025.

Elanco expects adjusted gross margin of 55.8% to 56.0%, an increase of 100 basis
points versus 2025 and compared to the prior expectation of 50 basis points of
improvement. Adjusted EBITDA guidance reflects savings from the Elanco Ascend
initiative as well as incremental strategic investments in the global launches
of the company's innovation portfolio and the advancement of the R&D pipeline.

Additionally, the company is providing guidance for the fourth quarter of 2026,
as summarized in the following table:
                                                                               
  2026 Fourth Quarter                                Guidance                  
  (dollars in millions, except per share amounts)                              
  Revenue(1)                                           $1,190    to    $1,215  
  Adjusted EBITDA                                        $185    to      $200  
  Adjusted Earnings per Share                           $0.16    to     $0.19  
                                                                               
(1) Revenue guidance excludes royalty revenue and sales-based milestones that
were sold to a third party.

In the fourth quarter, the company anticipates a minimal impact from foreign
exchange rates compared to prior year. Excluding the impacts of foreign exchange
rates, the AHV International acquisition that closed in April 2026, and royalty
revenue and sales-based milestones sold to a third party, the company expects 4%
to 6% revenue growth. The company expects operating expenses up approximately
11% year-over-year in constant currency with incremental support for innovation
products and R&D investments.

The 2026 full year and fourth quarter financial guidance reflects foreign
exchange rates as of the end of October. Further details on guidance, including
GAAP reported to non-GAAP adjusted reconciliations, are included in the
financial tables of this press release and will be discussed on the company's
conference call this morning.
                                       4                                        
                                                                                
   WEBCAST & CONFERENCE CALL DETAILS                                            
                                                                                
Elanco will host a webcast and conference call at 8:00 a.m. Eastern Time today,
during which company executives will review third quarter financial and
operational results, discuss fourth quarter and full year 2026 financial
guidance, provide an early outlook for the full year 2027, and respond to
questions from analysts. Investors, analysts, members of the media and the
public may access the live webcast and accompanying slides by visiting the
Elanco website at https://investor.elanco.com and selecting Events and
Presentations. A replay of the webcast will be archived and made available a few
hours after the event on the company's website, at
https://investor.elanco.com/news-events/events-presentation.
                                                                                
   ABOUT ELANCO                                                                 
                                                                                
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal
health dedicated to innovating and delivering products and services to prevent
and treat disease in farm animals and pets, creating value for farmers, pet
owners, veterinarians, stakeholders and society as a whole. With more than 70
years of animal health heritage, we are committed to breaking boundaries and
going beyond to help our customers improve the health of animals in their care,
while also making a meaningful impact on our local and global communities. At
Elanco, we are driven by our vision of Food and Companionship Enriching Life and
our purpose – to Go Beyond for Animals, Customers, Society and Our People. Learn
more at www.elanco.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
federal securities laws, including, without limitation, statements concerning
product launches and revenue from such products, our 2026 full year and fourth
quarter guidance and long-term expectations, our expectations regarding debt
levels, and expectations regarding our industry and our operations, performance
and financial condition, and including, in particular, statements relating to
our business, growth strategies, distribution strategies, product development
efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions
regarding our business, the economy and other future conditions. Because
forward-looking statements relate to the future, by their nature, they are
subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict. As a result, our actual results may differ materially from
those contemplated by the forward-looking statements. Important risk factors
that could cause actual results to differ materially from those in the forward-
looking statements include regional, national or global political, economic,
business, competitive, market and regulatory conditions, including but not
limited to the following:

• operating in a highly competitive industry;

• the success of our research and development (R&D), regulatory approval and
licensing efforts;

• the impact of disruptive innovations and advances in veterinary medical
practices, animal health technologies and alternatives to animal-derived
protein;

• competition from generic products that may be viewed as more cost-effective;

• changes in regulatory restrictions on the use of antibiotics in farm animals;

• an outbreak of infectious disease carried by farm animals;

• risks related to the evaluation of animals;

• consolidation of our customers and distributors;

• an increased use of alternative distribution channels or changes within
existing distribution channels;

• our dependence on the success of our top products;

• our ability to complete acquisitions and divestitures and to successfully
integrate the businesses we acquire;

• our ability to implement our business strategies or achieve targeted cost
efficiencies and gross margin improvements;

• manufacturing problems and capacity imbalances, including at our contract
manufacturers;

• fluctuations in inventory levels in our distribution channels;

• risks related to the use of artificial intelligence in our business;

• our dependence on sophisticated information technology systems and
infrastructure, including the use of third-party, cloud-based technologies, and
the impact of outages or breaches of the information technology systems and
infrastructure we rely on;

• the impact of weather conditions, including those related to climate change,
and the availability of natural resources;
                                       5                                        
• demand, supply and operational challenges associated with the effects of a
human disease outbreak, epidemic, pandemic or other widespread public health
concern;

• the loss of key personnel or highly skilled employees;

• adverse effects of labor disputes, strikes and/or work stoppages;

• the effect of our substantial indebtedness on our business, including
restrictions in our debt agreements that limit our operating flexibility and
changes in our credit ratings that lead to higher borrowing expenses and
restrict access to credit;

• changes in interest rates that adversely affect our earnings and cash flows;

• risks related to the write-down of goodwill or identifiable intangible assets;

• the lack of availability or significant increases in the cost of raw
materials;

• risks related to foreign and domestic economic, political, legal and business
environments;

• risks related to foreign currency exchange rate fluctuations;

• risks related to underfunded pension plan liabilities;

• our current plan not to pay dividends and restrictions on our ability to pay
dividends;

• the potential impact that actions by activist shareholders could have on the
pursuit of our business strategies;

• risks related to tax expense or exposures;

• actions by regulatory bodies, including as a result of their interpretation of
studies on product safety;

• the possible slowing or cessation of acceptance and/or adoption of our farm
animal sustainability initiatives;

• the impact of increased regulation or decreased governmental financial support
related to the raising, processing or consumption of farm animals;

• risks related to tariffs, trade protection measures or other modifications of
foreign trade policy;

• the impact of litigation, regulatory investigations and other legal matters,
including the risk to our reputation and the risk that our insurance policies
may be insufficient to protect us from the impact of such matters;

• challenges to our intellectual property rights or our alleged violation of
rights of others;

• misuse, off-label or counterfeiting use of our products;

• unanticipated safety, quality or efficacy concerns and the impact of
identified concerns associated with our products;

• insufficient insurance coverage against hazards and claims;

• compliance with privacy laws and security of information;

• risks related to environmental, health and safety laws and regulations; and

• inability to achieve our aspirations or meet the expectations of stakeholders
with respect to environmental, social and governance matters.

For additional information about the factors that could cause actual results to
differ materially from forward-looking statements, please see the company’s
latest Form 10-K and Form 10-Qs filed with the Securities and Exchange
Commission. Although we have attempted to identify important risk factors, there
may be other risk factors not presently known to us or that we presently believe
are not material that could cause actual results and developments to differ
materially from those made in or suggested by the forward-looking statements
contained in this press release. If any of these risks materialize, or if any of
the above assumptions underlying forward-looking statements prove incorrect,
actual results and developments may differ materially from those made in or
suggested by the forward-looking statements contained in this press release. We
caution you against relying on any forward-looking statements, which should also
be read in conjunction with the other cautionary statements that are included
elsewhere in this press release. Any forward-looking statement made by us in
this press release speaks only as of the date thereof. Factors or events that
could cause our actual results to differ may emerge from time to time, and it is
not possible for us to predict all of them. We undertake no obligation to
publicly update or to revise any forward-looking statement, whether as a result
of new information, future developments or otherwise, except as may be required
by law. Comparisons of results for current and any prior periods are not
intended to express any future trends or indications of future performance,
unless specifically expressed as such, and should be viewed as historical data.
                                       6                                        
                                                                                
   Use of Non-GAAP Financial Measures:                                          
                                                                                
We use non-GAAP financial measures, such as revenue growth excluding the impact
of acquisitions and divestitures, foreign exchange rate effects, royalty revenue
and sales-based milestones sold to third party, EBITDA, adjusted EBITDA,
adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted gross
profit, adjusted gross margin, net debt and net debt leverage to assess and
analyze our operational results and trends as explained in more detail in the
reconciliation tables later in this release.

We believe these non-GAAP financial measures are useful to investors because
they provide greater transparency regarding our operating performance.
Reconciliation of non-GAAP financial measures and reported U.S. generally
accepted accounting principles (GAAP) financial measures are included in the
tables accompanying this press release and are posted on our website at
www.elanco.com. The primary material limitations associated with the use of such
non-GAAP measures as compared to GAAP results include the following: (i) they
may not be comparable to similarly titled measures used by other companies,
including those in our industry, (ii) they exclude financial information and
events, such as the effects of an acquisition or divestiture or amortization of
intangible assets, that some may consider important in evaluating our
performance, value or prospects for the future, (iii) they exclude items or
types of items that may continue to occur from period to period in the future
and (iv) they may not exclude all unusual or non-recurring items, which could
increase or decrease these measures, which investors may consider to be
unrelated to our long-term operations. These non-GAAP measures are not, and
should not, be viewed as substitutes for GAAP reported measures. We encourage
investors to review our unaudited consolidated financial statements in their
entirety and caution investors to use GAAP measures as the primary means of
evaluating our performance, value and prospects for the future, and non-GAAP
measures as supplemental measures.
                                                                                
  Availability of Certain Information                                           
                                                                                
We use our website to disclose important company information to investors,
customers, employees and others interested in Elanco. We encourage investors to
consult our website regularly for important information about Elanco, including
an Investor Overview presentation containing a general overview of the business,
which can be found in the Events and Presentations page of our website.
                                                                                
  Additional Information                                                        
                                                                                
We define innovation revenue as revenue from new products, lifecycle management
and certain geographic expansions and business development transactions that is
incremental in reference to product revenue in 2020 and does not include the
expected impact of cannibalization on the base portfolio.

We define organic constant currency revenue growth as revenue growth excluding
royalty revenue and sales-based milestones that were sold to a third party, the
impact of foreign exchange rates, and revenue attributable to AHV International
B.V., which was acquired on April 30, 2026.
                                       7                                        
                                                                                
                       Elanco Animal Health Incorporated                        
                                                                                
                                                                                
           Unaudited Condensed Consolidated Statements of Operations            
                                                                                
            (Dollars and shares in millions, except per share data)             
                                                                                
              Th…                                  Ni…                          
              Mo…                                  Mo…                          
              En…                                  En…                          
              Se…                                  Se…                          
        2026  30,          20…               2026  30,          20…             
 ────────────────────────────────────────────────────────────────────────────── 
  R…    $     1,…          $    1,1…         $     4,…          $    3,5…       
  C…                                                                            
  of          545                530               1,…               1,5…       
  s…                                                                            
  G…          720                607               2,…               2,0…       
  p…                                                                            
  R…                                                                            
  a…           99                 89               288                275       
  d…                                                                            
  M…                                                                            
  s…          393                351               1,…               1,0…       
  a…                                                                            
  a…                                                                            
  A…                                                                            
  of          144                140               421                404       
  i…                                                                            
  a…                                                                            
  A…                                                                            
  i…                                                                            
  r…                                                                            
  a…            3                 25                28                 35       
  o…                                                                            
  s…                                                                            
  c…                                                                            
  I…                                                                            
  e…                                                                            
  n…           59                 52               175                140       
  of                                                                            
  c…                                                                            
  i…                                                                            
  O…                                                                            
  (…           -2                  —                 1                 23       
  e…                                                                            
  n…                                                                            
  I…                                                                            
  (…                                                                            
  b…           24                -50               167                 35       
  i…                                                                            
  t…                                                                            
  I…                                                                            
  t…            6                -16                38                 -9       
  e…                                                                            
  (…                                                                            
  N…                                                                            
  i…    $      18          $     -34         $     129          $      44       
  (…                                                                            
  E…                                                                            
  p…                                                                            
  s…                                                                            
  B…    $     0.…          $    -0.…         $     0.…          $    0.09       
  D…    $     0.…          $    -0.…         $     0.…          $    0.09       
  W…                                                                            
  s…                                                                            
  o…                                                                            
  B…               499…               49…               498…               49…  
  D…               506…               49…               506…               50…  
                                                                                
                                       8                                        
                                                                                
                       Elanco Animal Health Incorporated                        
                                                                                
   Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information    
                                                                                
                                  (Unaudited)                                   
                                                                                
            (Dollars and shares in millions, except per share data)             
We use non-GAAP financial measures, such as organic constant currency revenue
growth, adjusted gross profit, adjusted gross margin percentage, adjusted net
income, adjusted EPS, EBITDA, adjusted EBITDA and adjusted EBITDA margin and net
debt and net debt leverage, that differ from financial measures reported in
conformity with GAAP. The company believes these non-GAAP measures provide
useful information to investors. Among other things, they may help investors
assess and analyze our operational results and trends of our ongoing operations.
Management also uses these non-GAAP measures internally to evaluate the
performance of the business and in making resource allocation decisions.
Investors should consider these non-GAAP measures in addition to, not as a
substitute for or superior to, measures of financial performance prepared in
accordance with GAAP. Reconciliation of non-GAAP financial measures and reported
GAAP financial measures are included in the tables below.
                                                                                
  Adjusted Gross Profit and Gross Margin Percentage                             
                                                                                
We define gross profit as total revenue less cost of sales. We define adjusted
gross profit as gross profit less royalty revenue and sales-based milestones
sold to a third party, less cost of sales adjustments. We define adjusted gross
margin percentage as adjusted gross profit divided by total revenue, less
royalty revenue and sales-based milestones sold to a third party. The following
is a reconciliation of GAAP reported gross profit for the three and nine months
ended September 30, 2026 and 2025, to adjusted gross profit and adjusted gross
margin percentage:
                                                                                
                Three                                Nine                       
                Mont…                              Months                       
                Ended                               Ended                       
                Sept…                              Septe…                       
          2026    30,       2025             2026     30,       2025            
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  rep…    $       720       $      607       $      2,303       $     2,004     
  gro…                                                                          
  pro…                                                                          
  Sold                                                                          
  roy…                                                                          
  and             -21               -6                -39               -10     
  mil…                                                                          
  rev…                                                                          
  Cost                                                                          
  of                —                —                  —                 1     
  sal…                                                                          
  adj…                                                                          
  Adj…                                                                          
  gro…    $       699       $      601       $      2,264       $     1,995     
  pro…                                                                          
  Adj…                                                                          
  gro…           56.1  %          53.1  %            57.1  %           56.0  %  
  mar…                                                                          
  per…                                                                          
                                                                                
                                                                                
  Adjusted Net Income and Earnings Per Share                                    
                                                                                
We define adjusted net income as net income excluding amortization of intangible
assets, purchase accounting adjustments to inventory, acquisition and
divestiture-related charges, including integration and separation costs,
severance, goodwill and other asset impairments, gains on sales of assets and
related costs, facility exit costs, the impacts from sales of future revenues,
gains and losses on mark-to-market adjustments on equity securities, tax
valuation allowances, certain litigation-related settlements that we consider to
be unusual or infrequent and significant, and other specified significant items,
such as unusual or non-recurring items that are unrelated to our long-term
operations adjusted for income tax expense associated with the excluded
financial items. We define adjusted earnings per share as adjusted net income
divided by the number of weighted-average diluted shares outstanding for the
applicable period. The following is a reconciliation of GAAP reported net income
and EPS for the three months ended September 30, 2026 and 2025, to adjusted net
income and EPS:
                                                                                
                        Three                              Three                
                       Months                             Months                
                        Ended                              Ended                
                     Septemb…                           Septemb…                
                     30, 2026                           30, 2025                
 ────────────────────────────────────────────────────────────────────────────── 
            Net                  EPS           Net(lo…              EPS         
            income…                            income…                          
  GAAP                                                                          
  repor…                                                                        
  net                                                                           
  income    $              18    $     0.04    $             -34    $    -0.07  
  (loss)                                                                        
  and                                                                           
  EPS                                                                           
  Amort…                                                                        
  of                      144          0.28                  140          0.28  
  intan…                                                                        
  assets                                                                        
  Asset                                                                         
  impai…                                                                        
  restr…                                                                        
  and                       3          0.01                   25          0.05  
  other                                                                         
  speci…                                                                        
  charg…                                                                        
  Sold                                                                          
  royal…                                                                        
  and                     -21         -0.04                   -6         -0.01  
  miles…                                                                        
  reven…                                                                        
  Inter…                                                                        
  expen…                                                                        
  net of                   18          0.03                   18          0.04  
  capit…                                                                        
  inter…                                                                        
  Other                                                                         
  incom…                    —             —                    1          0.00  
  net                                                                           
  Income                                                                        
  tax                     -26         -0.05                  -50         -0.10  
  expen…                                                                        
  (bene…                                                                        
  Adjus…                                                                        
  net                                                                           
  income    $             136    $     0.27    $              94    $     0.19  
  and                                                                           
  EPS                                                                           
                                                                                
                                       9                                        
(a) Adjustments to GAAP reported net income to arrive at adjusted net income for
the three months ended September 30, 2026 and 2025, included the following:

(1) Adjustments of $25 million for the three months ended September 30, 2025,
primarily related to two early-stage capital projects totaling $16 million that
were indefinitely suspended during the third quarter.

(2) Adjustments of $18 million for the three months ended September 30, 2026,
primarily related to imputed interest expense on our liability for sale of
future revenue. Adjustments of $18 million for the three months ended September
30, 2025, primarily related to $13 million of imputed interest expense on our
liability for sale of future revenue, and to a lesser degree, the write-off of
previously deferred financing costs, given accelerated principal repayments.

(3) Adjustments of $26 million for the three months ended September 30, 2026,
primarily represented the income tax expense associated with the adjusted items
discussed above. Adjustments of $50 million for the three months ended September
30, 2025 primarily represented the income tax expense associated with the
adjusted items discussed above and the discrete tax impact from the
remeasurement of certain deferred tax positions due to a foreign tax rate
change.

The following is a reconciliation of GAAP reported net income and EPS for the
nine months ended September 30, 2026 and 2025, to adjusted net income and EPS:
                                                                                
                     Nine                             Nine                      
                   Months                           Months                      
                    Ended                            Ended                      
                   Septe…                          Septem…                      
                      30,                              30,                      
                     2026                             2025                      
 ────────────────────────────────────────────────────────────────────────────── 
           Net               EPS           Netin…             EPS               
           incom…                                                               
  GAAP                                                                          
  repo…                                                                         
  net      $          129    $     0.26    $            44    $     0.09        
  inco…                                                                         
  and                                                                           
  EPS                                                                           
  Cost                                                                          
  of                    —             —                  1                0.00  
  sales                                                                         
  Amor…                                                                         
  of                  421          0.83                404          0.81        
  inta…                                                                         
  asse…                                                                         
  Asset                                                                         
  impa…                                                                         
  rest…                                                                         
  and                  28          0.06                 35          0.07        
  other                                                                         
  spec…                                                                         
  char…                                                                         
  Sold                                                                          
  roya…                                                                         
  and                 -39         -0.08                -10         -0.02        
  mile…                                                                         
  reve…                                                                         
  Inte…                                                                         
  expe…                                                                         
  net                  47          0.09                 28          0.06        
  of                                                                            
  capi…                                                                         
  inte…                                                                         
  Other                                                                         
  (inc…                15          0.03                  5          0.01        
  expe…                                                                         
  net(…                                                                         
  Inco…                                                                         
  tax                 -87         -0.17                -98         -0.20        
  expe…                                                                         
  (ben…                                                                         
  Adju…                                                                         
  net                                                                           
  inco…    $          514    $     1.02    $           409    $     0.82        
  and                                                                           
  EPS                                                                           
                                                                                
(a) Adjustments to GAAP reported net income to arrive at adjusted net income for
the nine months ended September 30, 2026 and 2025, included the following:

(1) Adjustments of $28 million for the nine months ended September 30, 2026,
primarily related to $18 million of restructuring charges ($15 million of which
was non-cash shut-down costs for the animal studies portion of our R&D
facilities in Monheim, Germany) associated with our 2025 Restructuring Plan, as
well as costs associated with our acquisition of AHV ($5 million). Adjustments
of $35 million for the nine months ended September 30, 2025, included two early-
stage capital projects totaling $16 million that were indefinitely suspended
during the third quarter of 2025 and $7 million of upfront payments made in
relation to new licensing arrangements.

(2) Adjustments of $47 million for the nine months ended September 30, 2026,
primarily related to imputed interest expense on our liability for sale of
future revenue. Adjustments of $28 million for the nine months ended September
30, 2025, primarily related to $20 million of imputed interest expense on our
liability for sale of future revenue and the write-off of previously deferred
financing costs, given accelerated principal repayments made throughout 2025.

(3) Adjustments of $15 million for the nine months ended September 30, 2026,
primarily related to currency translation losses reclassified from accumulated
other comprehensive loss in conjunction with the substantial liquidation of a
dormant legal entity, a litigation settlement, and mark-to-market adjustments on
equity investments.

(4) Adjustments of $87 million for the nine months ended September 30, 2026,
primarily represented the income tax expense associated with the adjusted items
discussed above. A djustments of $98 million for the nine months ended September
30, 2025, primarily represented the income tax expense associated with the
adjusted items discussed above and the discrete tax impacts from the
remeasurement of certain deferred tax positions due to foreign tax rate changes,
partially offset by a $35 million benefit related to a discrete tax item
recognized during the first quarter of 2025.
                                       10                                       
                                                                                
  Adjusted EBITDA and Adjusted EBITDA Margin                                    
                                                                                
We define adjusted EBITDA as net income (loss) adjusted for interest expense
(income), which includes debt financing charges and imputed interest on our
liability for sale of future revenue, income tax expense (benefit) and
depreciation and amortization, further adjusted to exclude purchase accounting
adjustments to inventory, acquisition and divestiture-related charges, including
integration and separation costs, severance, goodwill and other asset
impairments, gains on sales of assets and related costs, facility exit costs,
revenue sold to a third party, gains and losses on mark-to-market adjustments on
equity securities, certain litigation-related settlements which we consider to
be unusual or infrequent and significant, and other specified significant items,
such as unusual or non-recurring items that are unrelated to our long-term
operations.

For the periods presented, we have not made adjustments for all items that may
be considered unrelated to our long-term operations. We believe adjusted EBITDA,
when used in conjunction with our results presented in accordance with GAAP and
its reconciliation to net income (loss), enhances investors' understanding of
our performance, valuation and prospects for the future. We also believe
adjusted EBITDA is a measure used in the animal health industry by analysts as a
valuable performance metric for investors. The following is a reconciliation of
GAAP reported net income (loss) for the three and nine months ended September
30, 2026 and 2025, to EBITDA, adjusted EBITDA and adjusted EBITDA margin, which
we define as adjusted EBITDA divided by total revenue, less royalty revenue and
sales-based milestones sold to a third party, fo r the respective periods:
                                                                                
                 Three                                Nine                      
                 Mont…                              Months                      
                 Ended                               Ended                      
                 Sept…                              Septe…                      
           2026    30,       2025             2026     30,       2025           
 ────────────────────────────────────────────────────────────────────────────── 
  GAAP                                                                          
  repo…                                                                         
  net      $        18       $      -34       $        129       $       44     
  inco…                                                                         
  (los…                                                                         
  Net                                                                           
  inte…             59               52                175              140     
  expe…                                                                         
  Inco…                                                                         
  tax                6              -16                 38               -9     
  expe…                                                                         
  (ben…                                                                         
  Depr…                                                                         
  and              179              176                520              506     
  amor…                                                                         
  EBIT…    $       261       $      178       $        861       $      681     
  Non-…                                                                         
  adju…                                                                         
  Cost                                                                          
  of       $         —       $        —       $          —       $        1     
  sales                                                                         
  Asset                                                                         
  impa…                                                                         
  rest…                                                                         
  and                3               25                 28               35     
  other                                                                         
  spec…                                                                         
  char…                                                                         
  Sold                                                                          
  roya…                                                                         
  and              -21               -6                -39              -10     
  mile…                                                                         
  reve…                                                                         
  Other                                                                         
  (inc…              —                1                 15                5     
  expe…                                                                         
  net                                                                           
  Adju…    $       243       $      198       $        865       $      712     
  EBIT…                                                                         
  Adju…                                                                         
  EBIT…           19.5  %          17.5  %            21.8  %          20.0  %  
  marg…                                                                         
                                                                                
Numbers may not add due to rounding.
                                       11                                       
                                                                                
  Gross and Net Debt and Net Leverage Ratio                                     
                                                                                
We define gross debt as the sum of the current portion of long-term debt and
long-term debt excluding unamortized debt issuance costs. We define net debt as
gross debt less cash and cash equivalents and finance lease liabilities on the
balance sheet. We define our net leverage ratio as net debt divided by our
trailing twelve month adjusted EBITDA. We believe our net debt and net leverage
ratio are important measures to monitor our financial flexibility, liquidity and
capital structure and may enhance investors' understanding of our ability to
meet future financial obligations. In addition, a net leverage ratio is a
financial measure that is frequently used by investors and creditors. The below
calculations do not include covenant-related adjustments that reduce our net
leverage ratio. The following is a reconciliation of gross debt to net debt as
of September 30, 2026:
                                                     
  Long-term debt                           $  3,633  
  Current portion of long-term debt              74  
  Less: Unamortized debt issuance costs         -21  
  Total gross debt                            3,728  
  Less: Cash and cash equivalents               465  
  Less: Finance lease liabilities               258  
  Net debt                                 $  3,005  
                                                     
The following table presents a calculation of our net leverage ratio as of
September 30, 2026:
                                                           
  Net debt                                 $  3,005        
  Trailing twelve month adjusted EBITDA       1,053        
  Net leverage ratio                                 2.9x  
                                                           
                                       12                                       

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ELAN/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.